LONDON, June 12 (Reuters) – AstraZeneca has struck a
deal worth up to $232 million in milestone payments to acquire
rights to a drug from Synairgen for treating
respiratory tract viral infections in patients with severe
Britain’s second-biggest drugmaker – subject of a $118
billion bid by Pfizer that failed last month – said on
Thursday it would pay UK-based Synairgen a $7.25 million upfront
fee and potential development, regulatory and commercial
milestones of up to $225 million for rights to the drug,
LONDON, June 2 (Reuters) – Europe’s new one-stop patent
system is winning over companies despite initial criticism from
lawyers and some multinationals of the scheme, which is expected
to come into effect in 2016, according to a survey on Monday.
The Europe-wide unitary patent system offers a cheaper,
simpler solution for businesses seeking to protect their
inventions, rather than having to register and enforce patents
separately in individual European Union countries.
LONDON (Reuters) – GlaxoSmithKline has invited private equity firms to consider making offers for a range of its older drugs sold in Western markets, according to three people with direct knowledge of the matter.
The move is part of a reshaping of the drugmaker’s business, which also involves a major asset swap deal struck last month with Novartis.
LONDON, May 29 (Reuters) – A group of 53 leading scientists
has warned the World Health Organisation not to classify
e-cigarettes as tobacco products, arguing that doing so would
jeopardise a major opportunity to slash disease and deaths
caused by smoking.
The UN agency, which is currently assessing its position on
the matter, has previously indicated it would favour applying
similar restrictions to all nicotine-containing products.